Published in Cancer Res on August 15, 1991
Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A (1994) 1.75
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A (1993) 1.60
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer (1994) 1.07
A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma. Virchows Arch (2010) 0.96
Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer (1995) 0.84
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Br J Cancer (1993) 0.78
High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia. Br J Cancer (2012) 0.77
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells. Biochem Biophys Rep (2017) 0.75
Patterns of transcription of human cytomegalovirus in permissively infected cells. J Virol (1980) 3.08
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res (1979) 2.97
Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther (2008) 2.10
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
Comparative inactivation of viruses by chlorine. Appl Environ Microbiol (1980) 2.04
Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA. Clin Chem (1999) 1.77
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene (2007) 1.77
Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol (1988) 1.72
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A (1993) 1.60
The cell biology of multiple drug resistance. Biochem Pharmacol (1987) 1.55
Detection of herpesvirus type 6 by polymerase chain reaction in blood donors: random tests and prospective longitudinal studies. Br J Haematol (1994) 1.53
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol (1996) 1.51
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res (1987) 1.44
Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat Rep (1983) 1.43
Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact? J Natl Cancer Inst (1995) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res (2000) 1.41
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry (1988) 1.38
Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation (2001) 1.38
Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem (1999) 1.35
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A (1989) 1.34
Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens. J Clin Microbiol (1994) 1.29
LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res (1999) 1.27
Detection of human cytomegalovirus DNA by real-time quantitative PCR. J Clin Microbiol (2000) 1.24
Impalement injuries to the thorax as a result of motor vehicle accidents. Ann Thorac Surg (1987) 1.24
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol (2000) 1.22
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res (1987) 1.21
Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood (1994) 1.20
Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes (2002) 1.20
Antitopoisomerase drug action and resistance. Eur J Cancer (1996) 1.17
Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul (1993) 1.16
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther (2008) 1.15
Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res (1998) 1.14
Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res (2000) 1.12
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A (1991) 1.12
Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene (2010) 1.11
Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol (2001) 1.10
The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res (1999) 1.09
Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res (1999) 1.09
Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene (2006) 1.08
Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer Res (1982) 1.06
Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. Cancer Res (1989) 1.04
Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity. Exp Cell Res (1999) 1.04
Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res (1998) 1.02
A novel nuclear localization signal in human DNA topoisomerase I. J Biol Chem (2000) 1.00
Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv Enzyme Regul (1990) 0.99
Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Leukemia (2011) 0.99
Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol (1991) 0.98
The in vivo stimulation of rat liver ornithine decarboxylase activity by dibutyryl cyclic adenosine 3',5'-monophosphate, theophylline and dexamethasone. Biochem Biophys Res Commun (1972) 0.97
Preclinical evaluation of illudins as anticancer agents. Cancer Res (1987) 0.96
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein. Proc Natl Acad Sci U S A (1999) 0.96
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol (1996) 0.96
Characterization of multidrug resistance by fluorescent dyes. Cancer Res (1991) 0.95
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res (1998) 0.95
Platypnea-orthodeoxia as a cause of unexplained hypoxemia in an 82-yr-old female. Cathet Cardiovasc Diagn (1990) 0.95
Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res (2001) 0.95
Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg (2000) 0.94
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin Cancer Res (1998) 0.94
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry (1990) 0.94
Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells. Cancer Res (1985) 0.94
Herpesvirus type 6 in patients undergoing bone marrow transplantation: serologic features and detection by polymerase chain reaction. Blood (1994) 0.94
A potential role for human herpesvirus type 6 in nervous system disease. J Neuroimmunol (1994) 0.93
Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res (1986) 0.93
Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein. Biotechniques (1998) 0.92
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res (1999) 0.92
Cellular pharmacology of Vinca alkaloid resistance and its circumvention. Adv Enzyme Regul (1984) 0.92
Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia (1994) 0.92
Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol (1983) 0.92
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun (2000) 0.92
Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine. Cancer Treat Rep (1984) 0.91
Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells. Exp Cell Res (2000) 0.91
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res (1993) 0.90
Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment. Blood (2001) 0.89
Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol Pharmacol (1999) 0.89
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol (1997) 0.89
Opioid receptor density changes in Alzheimer amygdala and putamen. Brain Res (1993) 0.89
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol (1999) 0.88
Identification of human cytomegalovirus variants by analysis of single strand conformation polymorphism and DNA sequencing of the envelope glycoprotein B gene region-distribution frequency in liver transplant recipients. J Virol Methods (1999) 0.87
Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia (1993) 0.87
Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem Pharmacol (1986) 0.87
Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation (1994) 0.87
Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry (1995) 0.87
DNA damage signals induction of fas ligand in tumor cells. Mol Pharmacol (1999) 0.87
Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res (1990) 0.86
DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol Res (1995) 0.86
Human herpesvirus type 7 in blood donors: detection by the polymerase chain reaction. J Med Virol (1995) 0.86
Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer (1997) 0.86
Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res (1995) 0.86
Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol (1998) 0.86
Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin Cancer Res (1998) 0.86
Puromycin stimulation of rat liver ornithine decarboxylase activity. Nature (1973) 0.85
Administration of queuine to mice relieves modified nucleoside queuosine deficiency in Ehrlich ascites tumor tRNA. Biochem Biophys Res Commun (1980) 0.85